Comments
Aventis Pharma Ltd has paid Rs 567.1 crore as lumpsum consideration to Universal Medicare Pvt Ltd to acquire its marketing and distribution of branded nutraceutical formulations business in India for which it had earlier entered into a definitive agreement.
The transaction was closed on November 3 on fulfilment of all the conditions precedent and on closing, it paid a sum of Rs 567.1 crore as lumpsum consideration for the business as a going concern.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.